Is Silence Therapeutics (silence) a great stock to buy?

Silence Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $44.25, Silence Therapeutics has a forecasted upside of 398.9% from its current price of $8.87.

What happened to Silence Therapeutics plc?

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom. During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%.

When did Silence Therapeutics (SLN) become a company?

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?